Detection of fusion events by RNA sequencing in FFPE versus freshly frozen colorectal cancer tissue samples by Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Vladimir Lyadov, Vladimir Lyadov, Vladimir Lyadov, Maria Suntsova, Marat Garipov, Anna Semenova, Natalia Popova, Egor Guguchkin, Rustam Heydarov, Marianna Zolotovskaia, Xiaowen Zhao, Qing Yan, Ye Wang, Evgeny Karpulevich, Anton Buzdin, Anton Buzdin, Anton Buzdin, Anton Buzdin

“…Specific targeted therapies are available for several types of cancer fusions including receptor tyrosine kinase gene moieties. RNA sequencing (RNAseq) can directly be used for detection of gene rearrangements in a single test, along with multiple additional biomarkers. …”
Get full text

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion by Glen J. Weiss, Agnes K. Liman, Jeffrey Allen, Philip Y. Cheung, Rajesh N. Kukunoor

“…One of these patients received EGFR tyrosine kinase directed therapy for a brief period with some symptom relief. …”
Get full text

Discovery of a Novel DYRK1A Mutation (c.524del) in Intellectual Development Disorder Autosomal Dominant 7 (MRD7): A Comprehensive Case Analysis by Fiona Whitaker, Alvaro Serrano

“…Dual-specificity tyrosine kinase 1A (DYRK1A) is a member of the CMGC family that is linked to a multitude of neuronal development pathways. …”
Get full text

Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis by Mariana M. Sebastião, Rodrigo S. Ho, João Paulo V. de Carvalho, Micha Nussbaum

“…The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. …”
Get full text

A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment by Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy

“…This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy. …”
Get full text

New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies by Ping Wang, Aitor Aguirre

“…Despite significant advances in recent years, such as the introduction of targeted therapies such as receptor tyrosine kinase inhibitors and immunotherapy, current approaches are insufficient to stop the advance of the disease and many cancer types remain largely intractable. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. …”
Get full text

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment by S. Lanfranconi, S. Corti, P. Baron, G. Conti, L. Borellini, N. Bresolin, A. Bersano

“…Muscle-specific tyrosine kinase- (MuSK-) antibodies-positive Myasthenia Gravis accounts for about one third of Seronegative Myasthenia Gravis and is clinically characterized by early onset of prominent bulbar, neck, shoulder girdle, and respiratory weakness. …”
Get full text

Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature by Bader Alharbi, Samer Alamri, Ahmed Mahdi, Siham Marghalani

“…Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. …”
Get full text

A Case Report with Severe Thrombocytopenia Induced by Axitinib by Ulkuhan I. Koksal, Janeiro Valle Goffin, Brian Lewis, Oliver A. Sartor, Elizaveta Belyaeva, Francisco Socola, Pedro C. Barata

“…Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). …”
Get full text

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece by George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba

“…Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-positive NSCLC previously treated with at least one second-generation ALK tyrosine kinase inhibitor. **Objective:** The present study assessed the cost-effectiveness of lorlatinib vs pemetrexed with platinum combination of carboplatin or cisplatin (P-ChT) in Greece. …”
Get full text

Inhibition of IGF-1R-Dependent PI3K Activation Sensitizes Colon Cancer Cells Specifically to DR5-Mediated Apoptosis But Not to rhTRAIL by Bodvael Pennarun, Jan H. Kleibeuker, Tjitske Oenema, Janet H. Stegehuis, Elisabeth G.E. de Vries, Steven de Jong

“…We hypothesized that inhibiting the IGF-1 receptor (IGF-1R) using NVP-AEW541, a small molecular weight tyrosine kinase inhibitor of the IGF-1R, could increase death receptor (DR)-mediated apoptosis in colon cancer cells.…”
Get full text

Tailored Therapy in Lung Cancer by George Rakovich, Lise Tremblay

“…Advances in molecular biology have made possible the development of drugs against specific molecular targets on cancer cells, most notably the tyrosine kinase inhibitors. The relevant literature and current practice guidelines are discussed. …”
Get full text

The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy by Jan-Henrik Mikesch, Kathrin Schier, Antje Roetger, Ronald Simon, Horst Buerger, Burkhard Brandt

“…Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. …”
Get full text

Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature by Kyle Kreitman, Satheesh P. Nair, Jiten P. Kothadia

“…Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. …”
Get full text

Rapid Evaluation of Mutant Exon-11 in c-kit in a Recurrent MCT Case Using CD117 Immunocytofluorescence, FACS-Cell Sorting, and PCR by Dettachai Ketpun, Achariya Sailasuta, Prapruddee Piyaviriyakul, Nattawat Onlamoon, Kovit Pattanapanyasat

“…The owner and the veterinarian would like to use a tyrosine kinase inhibitor (TKI) for the dog. Therefore, fine-needle aspiration (FNA) was performed to collect the MCT cells and these cells were submitted to our laboratory for the detection of internal-tandem-duplicated (ITD) mutation of exon-11 in c-kit, prior to the treatment. …”
Get full text

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia by Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Hervé Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Pierre Peterlin, Simon Bouzy, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Martin Carre, Sylvie Tondeur, Lamya Haddaoui, Raphael Itzykson, Sarah Bertoli, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Christian Récher, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

“…Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases. …”
Get full text

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias by Alessandro Morotti, Giovanna Carrà, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio, Giuseppe Saglio

“…BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. …”
Get full text

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia by Álvaro Taus, Flavio Zuccarino, Carlos Trampal, Edurne Arriola

“…EGFR-activating mutation allowed us to start treatment with the oral tyrosin kinase inhibitor Gefitinib, obtaining a rapid and sustained response. …”
Get full text

Recurrence of Chronic Myeloid Leukemia during Pregnancy Subsequently Achieving Complete Medical Remission by Sasha Mikhael, Ashlee Pascoe, Joseph Prezzato

“…The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) in reproductive-aged women poses major dilemmas concerning its associated teratogenicity as observed in many animal studies. …”
Get full text